These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32518267)

  • 1. Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen.
    Wu D; Gallagher DT; Gowthaman R; Pierce BG; Mariuzza RA
    Nat Commun; 2020 Jun; 11(1):2908. PubMed ID: 32518267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell receptors employ diverse strategies to target a p53 cancer neoantigen.
    Wu D; Gowathaman R; Pierce BG; Mariuzza RA
    J Biol Chem; 2022 Mar; 298(3):101684. PubMed ID: 35124005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
    Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
    Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.
    Borbulevych OY; Insaidoo FK; Baxter TK; Powell DJ; Johnson LA; Restifo NP; Baker BM
    J Mol Biol; 2007 Oct; 372(5):1123-36. PubMed ID: 17719062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.
    Kim SP; Vale NR; Zacharakis N; Krishna S; Yu Z; Gasmi B; Gartner JJ; Sindiri S; Malekzadeh P; Deniger DC; Lowery FJ; Parkhurst MR; Ngo LT; Ray S; Li YF; Hill V; Florentin M; Masi RV; Paria BC; Levin N; Bera A; Hedges EA; Choi A; Chatani PD; Parikh AY; Levi S; Seitter S; Lu YC; Zheng Z; Prickett TD; Jia L; Hernandez JM; Hoang CD; Robbins PF; Goff SL; Sherry RM; Yang JC; Rosenberg SA
    Cancer Immunol Res; 2022 Aug; 10(8):932-946. PubMed ID: 35749374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity.
    Mariuzza RA; Wu D; Pierce BG
    Front Immunol; 2023; 14():1303304. PubMed ID: 38045695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer.
    Lo W; Parkhurst M; Robbins PF; Tran E; Lu YC; Jia L; Gartner JJ; Pasetto A; Deniger D; Malekzadeh P; Shelton TE; Prickett T; Ray S; Kivitz S; Paria BC; Kriley I; Schrump DS; Rosenberg SA
    Cancer Immunol Res; 2019 Apr; 7(4):534-543. PubMed ID: 30709841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
    Shilyansky J; Nishimura MI; Yannelli JR; Kawakami Y; Jacknin LS; Charmley P; Rosenberg SA
    Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2829-33. PubMed ID: 7511820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors.
    Wang Z; Turner R; Baker BM; Biddison WE
    J Immunol; 2002 Sep; 169(6):3146-54. PubMed ID: 12218132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
    Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.
    Chheda ZS; Kohanbash G; Okada K; Jahan N; Sidney J; Pecoraro M; Yang X; Carrera DA; Downey KM; Shrivastav S; Liu S; Lin Y; Lagisetti C; Chuntova P; Watchmaker PB; Mueller S; Pollack IF; Rajalingam R; Carcaboso AM; Mann M; Sette A; Garcia KC; Hou Y; Okada H
    J Exp Med; 2018 Jan; 215(1):141-157. PubMed ID: 29203539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer.
    Dao T; Klatt MG; Korontsvit T; Mun SS; Guzman S; Mattar M; Zivanovic O; Kyi CK; Socci ND; O'Cearbhaill RE; Scheinberg DA
    Cancer Immunol Immunother; 2021 May; 70(5):1189-1202. PubMed ID: 33123756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
    Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
    Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unraveling a hotspot for TCR recognition on HLA-A2: evidence against the existence of peptide-independent TCR binding determinants.
    Gagnon SJ; Borbulevych OY; Davis-Harrison RL; Baxter TK; Clemens JR; Armstrong KM; Turner RV; Damirjian M; Biddison WE; Baker BM
    J Mol Biol; 2005 Oct; 353(3):556-73. PubMed ID: 16197958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors.
    Lu D; Chen Y; Jiang M; Wang J; Li Y; Ma K; Sun W; Zheng X; Qi J; Jin W; Chen Y; Chai Y; Zhang CWH; Liang H; Tan S; Gao GF
    Nat Commun; 2023 Oct; 14(1):6389. PubMed ID: 37828002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction.
    Simpson AA; Mohammed F; Salim M; Tranter A; Rickinson AB; Stauss HJ; Moss PA; Steven NM; Willcox BE
    Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21176-81. PubMed ID: 22160697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
    Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB
    Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.